ArticleClinical cancer research : an official journal of the American Association for Cancer Research2023

FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement.

Timil H Patel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.